Cargando…

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib

A signaling pathway that is frequently deregulated in human carcinomas and has been explored as a therapeutic target involves the activation of the epidermal growth factor receptor (EGFR). Inhibition of EGFR via the small molecule inhibitors erlotinib and gefitinib commonly results in tumor resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernando, Romaine I., Hamilton, Duane H., Dominguez, Charli, David, Justin M., McCampbell, Kristen K., Palena, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173114/ https://www.ncbi.nlm.nih.gov/pubmed/27248176 http://dx.doi.org/10.18632/oncotarget.9662

Ejemplares similares

The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
por: David, Justin M., et al.
Publicado: (2016)

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
por: David, Justin M., et al.
Publicado: (2017)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas
por: Fernando, Romaine I, et al.
Publicado: (2013)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
por: Palena, Claudia, et al.
Publicado: (2014)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
por: Hamilton, Duane H, et al.
Publicado: (2013)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
por: Dominguez, Charli, et al.
Publicado: (2016)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition
por: David, Justin M., et al.
Publicado: (2016)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer
por: Zhang, Xu, et al.
Publicado: (2020)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Renal stem cells: fact or science fiction?
por: McCampbell, Kristen K., et al.
Publicado: (2012)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy
por: Horn, Lucas A., et al.
Publicado: (2021)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
por: Fousek, Kristen, et al.
Publicado: (2023)

Atlas of Cellular Dynamics during Zebrafish Adult Kidney Regeneration
por: McCampbell, Kristen K., et al.
Publicado: (2015)

Analysis of Nephron Composition and Function in the Adult Zebrafish Kidney
por: McCampbell, Kristen K., et al.
Publicado: (2014)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
por: Tang, Joy, et al.
Publicado: (2013)

Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non–Small Cell Lung Cancer Cells()
por: Saygideğer-Kont, Yasemin, et al.
Publicado: (2016)

THE OPHTHALMO-TUBERCULIN REACTION IN CATTLE
por: McCampbell, Eugene F.
Publicado: (1908)

FURTHER STUDIES ON THE OPHTHALMO-TUBERCULIN REACTION IN CATTLE
por: McCampbell, Eugene F.
Publicado: (1908)

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
por: Yano, Yukihiro, et al.
Publicado: (2012)

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer
por: Makris, Demosthenes, et al.
Publicado: (2007)

Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype
por: VATU, BOGDAN IONEL, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s81b1sro6insulem9jfidhc2r6